


The NeuroStar<sup>®</sup> TMS Outcomes Registry has evaluable data on over 5,200 patients since being initiated in Sept 2016, making it the **largest data set in Major Depressive Disorder**, surpassing STAR\*D.

	NeuroStar Outcomes Registry <sup>1</sup>	STAR*D Study <sup>2</sup>
Number of Sites	108 sites (ongoing recruitment)	41 sites
Total # Enrolled	8,977 patients	4,041 patients
Total # Evaluable	5,230 patients	3,671 patients

- In these **real-world outcomes**, by clinician rating (CGI-S) 73% patients respond to an acute course of NeuroStar, and **52% achieve remission**.
- On a patient rated scale (PHQ-9) 62% of patients achieved response and 33% achieved remission with an acute course of NeuroStar.
- The TrakStar<sup>®</sup> data management system makes automated large-scale data collection feasible.
- These treatment outcomes are comparable with NeuroStar open-label study data.<sup>3</sup>



DEMOGRAPHICS AND CLINICAL CHARACTERISTICS		
	PHQ-9	CGI-S
<b>Gender</b>		
Female, N (%)	3323 (64%)	1044 (61%)
Male, N (%)	1902 (36%)	664 (39%)
Other, N (%)	5 (0%)	0 (0%)
<b>Age</b>		
N	5230	1708
Mean ± SD	47.7 ± 16.8	47.5 ± 16.3
Median (Min, Max)	49 (0, 364)	48 (0, 103)

1. Data on file Neuronetics, 01 May 2020.
2. Rush (2006) *N Engl J Med*, 354(12):1231-42.
3. Carpenter LL, et. al. (2012). *Depress Anxiety*, 29(7):587-596.

NeuroStar<sup>®</sup> Advanced Therapy is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.